Below are the most recent publications written about "Iodine Radioisotopes" by people in Profiles.
-
Calabresi K, Emrich J, Belko S, Pugliese R, Komarnicky-Kocher L, Mourtada F. 3D-printed template design to improve 125I seed plaque assembly accuracy for uveal brachytherapy. Brachytherapy. 2025 May-Jun; 24(3):420-430.
-
Brose MS, Capdevila J, Elisei R, Bastholt L, F?hrer-Sakel D, Leboulleux S, Sugitani I, Taylor MH, Wang Z, Wirth LJ, Worden FP, Bernard J, Caferra P, Colzani RM, Liu S, Schlumberger M. Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy. Endocr Relat Cancer. 2024 08 01; 31(8).
-
Cahoon EK, Grimm E, Mabuchi K, Mai JZ, Zhang R, Drozdovitch V, Hatch M, Little MP, Peters KO, Bogdanova TI, Shelkovoy E, Shpak VM, Terekhova G, Zamotayeva G, Pasteur IP, Masiuk SV, Chepurny M, Zablotska LB, McConnell R, O'Kane P, Tronko MD, Brenner AV. Prevalence of Thyroid Nodules in Residents of Ukraine Exposed as Children or Adolescents to Iodine-131 from the Chornobyl Accident. Thyroid. 2024 07; 34(7):890-898.
-
Cappelli L, Emrich J, Komarnicky-Kocher L, Vinogradskiy Y, Mourtada F. I-125 eye-plaque seed economics: To re-use or to not re-use? A single institutional cost savings analysis of re-using I-125 radioactive seeds for eye-Plaque brachytherapy. Brachytherapy. 2024 Jul-Aug; 23(4):463-469.
-
Wang W, Emrich J, Mourtada F. J Appl Clin Med Phys. 2024 Aug; 25(8):e14395.
-
Bischoff LA, Ganly I, Fugazzola L, Buczek E, Faquin WC, Haugen BR, McIver B, McMullen CP, Newbold K, Rocke DJ, Russell MD, Ryder M, Sadow PM, Sherman E, Shindo M, Shonka DC, Singer MC, Stack BC, Wirth LJ, Wong RJ, Randolph GW. Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update. JAMA Otolaryngol Head Neck Surg. 2024 03 01; 150(3):265-272.
-
Ulloa-Padilla JP, Burkat CN, Morgenstern KE. Topical Application of Perchlorate: A Toxicity Study in Rats. Ophthalmic Plast Reconstr Surg. 2024 Mar-Apr 01; 40(2):198-200.
-
Gianoukakis AG, Choe JH, Bowles DW, Brose MS, Wirth LJ, Owonikoko T, Babajanyan S, Worden FP. Real-world practice patterns and outcomes for RAI-refractory differentiated thyroid cancer. Eur Thyroid J. 2024 02 01; 13(1).
-
Capdevila J, Krajewska J, Hernando J, Robinson B, Sherman SI, Jarzab B, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Williamson D, Levytskyy R, Oliver J, Keam B, Brose MS. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 2024 03; 34(3):347-359.
-
Subbiah V, Hu MI, Mansfield AS, Taylor MH, Schuler M, Zhu VW, Hadoux J, Curigliano G, Wirth L, Gainor JF, Alonso G, Adkins D, Godbert Y, Ahn MJ, Cassier PA, Cho BC, Lin CC, Zalutskaya A, Barata T, Trask P, Scalori A, Bordogna W, Heinzmann S, Brose MS. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2024 01; 34(1):26-40.